Variable | Baseline (N=133) | Follow-up | P value |
Age (years) | 33 (26–43) | N/A | |
Female sex, n (%) | 97 (73) | N/A | |
WHO-FC (Ⅰ/Ⅱ/III/IV), n | 3/17/89/24 | 10/86/35/2 | <0.001 |
6-MWD (m) | 375±120 | 454±102 | <0.001 |
BNP (pg/mL) | 180 (55–446) | 40 (14–162) | <0.001 |
Mean RAP (mm Hg) | 5 (3–8) | 4 (3–7) | 0.155 |
Mean PAWP (mm Hg) | 6 (4–8) | 6 (5–9) | 0.01 |
Mean PAP (mm Hg) | 56±14 | 48±16 | <0.001 |
SvO2 (%) | 62±10 | 67±9 | <0.001 |
Cardiac index (L/min/m2) | 1.80 (1.58–2.39) | 2.51 (1.94–3.18) | <0.001 |
SVI (mL/m2) | 26.8 (18.8–34.3) | 35.5 (25.7–46.1) | <0.001 |
PVR (WU) | 17.0 (11.7–23.9) | 10.6 (5.8–17.7) | <0.001 |
ERS/ESC risk score, n (%) | <0.001 | ||
Low risk | 25 (19) | 73 (55) | |
Intermediate risk | 86 (65) | 57 (43) | |
High risk | 22 (17) | 3 (2) | |
Medication | |||
ERA, n (%) | 53 (40) | N/A | |
PDE-5i, n (%) | 40 (30) | N/A | |
Riociguat, n (%) | 4 (3) | N/A | |
Epoprostenol, n (%) | 70 (53) | N/A | |
Epoprostenol dose (ng/kg/min) | 21 (12–30) | N/A | |
Selexipag, n (%) | 1 (1) | N/A | |
CCB, n (%) | 6 (5) | N/A | |
Double therapy, n (%) | 12 (9) | N/A | |
Triple therapy, n (%) | 36 (27) | N/A |
Values are presented as mean±SD, median (IQR) or n (%).
BNP, B-type natriuretic peptide; CCB, calcium channel blocker; ERA, endothelin receptor antagonist; ERS, European Respiratory Society; ESC, European Society of Cardiology; 6-MWD, 6 min walk distance; N/A, not applicable; PAP, mean pulmonary artery pressure; PAWP, pulmonary arterial wedge pressure; PDE-5i, phosphodiesterase type five inhibitor; PVR, pulmonary vascular resistance; RAP, right atrial pressure; SVI, stroke volume index; SvO2, mixed venous oxygen saturation; WHO-FC, WHO functional class; WU, Wood unit.